Patient concerns regarding antidepressant drug–drug interactions: a retrospective analysis using data from a medicines call centre
Edgar L. Poon
1 2 3 , Hyang Joo Lim 1 , Samantha A. Hollingworth 1 , Mieke L. van Driel 4 , David M. Pache 1 2 5 , Geraldine M. Moses 1 2 , Treasure M. McGuire 1 2 5 *
+ Author Affiliations
- Author Affiliations
1 School of Pharmacy, The University of Queensland, Brisbane, Qld, Australia.
2 Mater Pharmacy, Mater Health South East Queenland, Brisbane, Qld, Australia.
3 Greenslopes Private Hospital, Ramsay Health, Brisbane, Qld, Australia.
4 Faculty of Medicine, The University of Queensland, Brisbane, Qld, Australia.
5 Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Qld, Australia.
* Correspondence to: t.mcguire@uq.edu.au
Journal of Primary Health Care 14(2) 99-108 https://doi.org/10.1071/HC21150
Published: 22 April 2022
© 2022 The Author(s) (or their employer(s)). Published by CSIRO Publishing on behalf of the Royal New Zealand College of General Practitioners. This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND)
Abstract
Introduction: Antidepressant use has increased over the last two decades, with Australia and New Zealand among the highest antidepressant users in Organisation for Economic Co-operation and Development (OECD) countries. Comorbidity and polypharmacy are common in antidepressant users, increasing the likelihood of interaction-related adverse drug events, which are frequently preventable.
Aim: We aimed to identify, profile, and analyse potential antidepressant drug–drug interactions in information-seeking antidepressant users.
Methods: We retrospectively analysed antidepressant-related drug–drug interaction enquiries from patients or carers who contacted a pharmacist-led Australian national medicines call centre over an 8-year period to determine patient characteristics, concomitant drugs involved, prevalence and type of antidepressant-related drug–drug interaction across life stages, and associated risks.
Results: Of 3899 antidepressant drug–drug interaction calls, the most frequent concomitant drugs were antipsychotics, opioids, benzodiazepines, and complementary medicines. Narrative analyses of 2011 calls identified 81.0% of patients with potential drug–drug interactions and 10.4% categorised with worrying symptoms. The most frequent drug–drug interaction risks were excessive sedation, increased anticholinergic effects, serotonin syndrome, and suicidal thoughts. Carers of children aged <15 years and older adults (65–74 years) were more likely to report experiencing worrying symptoms. Although more potential pharmacodynamic than pharmacokinetic interactions were recorded, pharmacokinetic interactions tended to have more significant clinical impact.
Discussion: Antidepressant users often have information gaps and safety concerns regarding drug–drug interactions that motivate help-seeking behaviour. Symptoms and drug–drug interaction consequences may be underestimated in these patients. Primary care health professionals have a role in proactively addressing the risk of drug–drug interactions to support benefit-risk assessment and shared decision-making.
Keywords: Antidepressive agents, call centre, drug information services, drug interactions, help-seeking behaviour, information-seeking behaviour, prescribing, primary care.
References
[1] Organisation for Economic Co-operation and Development. Health at a glance 2019. Paris: OECD Publishing; 2019.[2] Britt H, Miller GC, Henderson J, et al. General practice activity in Australia 2015–16. Sydney University Press; 2016.
[3] Australian Institute of Health and Welfare. Mental health services in Australia. Canberra: Australian Institute of Health and Welfare; 2021. Available at https://www.aihw.gov.au/reports/mental-health-services/mental-health-services-in-australia [Accessed 21 August 2021]
[4] Wilkinson S, Mulder RT. Antidepressant prescribing in New Zealand between 2008 and 2015. N Z Med J 2018; 131 52–9.
| 30408818PubMed |
[5] Caughey GE, Roughead EE, Shakib S, et al. Comorbidity of chronic disease and potential treatment conflicts in older people dispensed antidepressants. Age Ageing 2010; 39 488–94.
| Comorbidity of chronic disease and potential treatment conflicts in older people dispensed antidepressants.Crossref | GoogleScholarGoogle Scholar | 20511245PubMed |
[6] Hanlon JT, Wang X, Castle NG, et al. Potential underuse, overuse, and inappropriate use of antidepressants in older veteran nursing home residents. J Am Geriatr Soc 2011; 59 1412–20.
| Potential underuse, overuse, and inappropriate use of antidepressants in older veteran nursing home residents.Crossref | GoogleScholarGoogle Scholar | 21824120PubMed |
[7] Lai LL, Alvarez G, Dang L, et al. Prevalence and trend of potential drug–drug interaction among children with depression in U.S. outpatient settings. J Pharm Health Serv Res 2019; 10 393–9.
| Prevalence and trend of potential drug–drug interaction among children with depression in U.S. outpatient settings.Crossref | GoogleScholarGoogle Scholar |
[8] Calderón-Larrañaga A, Poblador-Plou B, González-Rubio F, et al. Multimorbidity, polypharmacy, referrals, and adverse drug events: Are we doing things well? Br J Gen Pract 2012; 62 e821–e6.
| Multimorbidity, polypharmacy, referrals, and adverse drug events: Are we doing things well?Crossref | GoogleScholarGoogle Scholar | 23211262PubMed |
[9] Coupland C, Hill T, Morriss R, et al. Antidepressant use and risk of adverse outcomes in people aged 20-64 years: Cohort study using a primary care database. BMC Med 2018; 16 36
| Antidepressant use and risk of adverse outcomes in people aged 20-64 years: Cohort study using a primary care database.Crossref | GoogleScholarGoogle Scholar | 29514662PubMed |
[10] Doucet J, Jego A, Noel D, et al. Preventable and non-preventable risk factors for adverse drug events related to hospital admissions in the elderly. Clin Drug Investig 2002; 22 385–92.
| Preventable and non-preventable risk factors for adverse drug events related to hospital admissions in the elderly.Crossref | GoogleScholarGoogle Scholar |
[11] Pache DM, Hollingworth SA, van Driel ML, McGuire TM. Does consumer medicines interest reflect medicines use? An observational study comparing medicines call center queries with medicines use. Res Social Adm Pharm 2019; 15 440–7.
| Does consumer medicines interest reflect medicines use? An observational study comparing medicines call center queries with medicines use.Crossref | GoogleScholarGoogle Scholar | 29935855PubMed |
[12] Eek E, van Driel M, Falk M, et al. Antidepressant use in Australia and Sweden—a cross-country comparison. Pharmacoepidemiol Drug Saf 2021; 30 409–17.
| Antidepressant use in Australia and Sweden—a cross-country comparison.Crossref | GoogleScholarGoogle Scholar | 33098321PubMed |
[13] World Health Organization. WHO collaborating centre for drug statistics methodology. Guidelines for ATC classification and DDD assignment. Norwegian Institute of Public Health; 2021. Available at https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/
[14] Youscript. United States: YouScript Inc, 2021. Available at: https://www.youscript.net/ [Accessed 20 March 2021]
[15] Baxter K, Preston CL (eds). Stockley’s interactions checker. London: Pharmaceutical Press; 2021. Available at http://www.medicinescomplete.com/publication/stockleys-drug-interactions/ [Accessed 20 March 2021]
[16] Rossi S (ed). Australian Medicines Handbook Adelaide: Australian Medicines Handbook Pty Ltd. 2021. Available at https://amhonline.amh.net.au/ [Accessed 20 March 2021]
[17] Accesspharmacy. United States: McGraw Hill LLC; 2021. Available at https://accesspharmacy.mhmedical.com/ [Accessed 20 March 2021]
[18] Natural Medicines [database on the internet]. Somerville (MA): Therapeutic Research Center LLC; 2021. Available at https://naturalmedicines.therapeuticresearch.com/ [Accessed 20 March 2021]
[19] Abbasi Nazari M, Khanzadeh Moqhadam N. Evaluation of pharmacokinetic drug interactions in prescriptions of intensive care unit (ICU) in a teaching hospital. Iran J Pharm Res 2010; 5 215–8.
| Evaluation of pharmacokinetic drug interactions in prescriptions of intensive care unit (ICU) in a teaching hospital.Crossref | GoogleScholarGoogle Scholar |
[20] U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. U.S. Department of Health and Human Services; 2017.
[21] Benchimol EI, Smeeth L, Guttmann A, et al. The reporting of studies conducted using observational routinely-collected health data (record) statement. PLoS Med 2015; 12 e1001885
| The reporting of studies conducted using observational routinely-collected health data (record) statement.Crossref | GoogleScholarGoogle Scholar | 26440803PubMed |
[22] Freeman MP. Complementary and alternative medicine (CAM): Considerations for the treatment of major depressive disorder. J Clin Psychiatry 2009; 70 4–6.
| Complementary and alternative medicine (CAM): Considerations for the treatment of major depressive disorder.Crossref | GoogleScholarGoogle Scholar | 19909686PubMed |
[23] National Institute for Health and Care Excellence. Clinical guidelines. Depression in adults: recognition and management [CG90]. London: National Institute for Health and Care Excellence (UK); 2009. Available at https://www.nice.org.uk/guidance/cg90 [Accessed 29 May 2021]
[24] Zhang T, Carleton BC, Prosser RJ, et al. The added burden of comorbidity in patients with asthma. J Asthma 2009; 46 1021–6.
| The added burden of comorbidity in patients with asthma.Crossref | GoogleScholarGoogle Scholar | 19995140PubMed |
[25] Beurel E, Toups M, Nemeroff CB. The bidirectional relationship of depression and inflammation: double trouble. Neuron 2020; 107 234–56.
| The bidirectional relationship of depression and inflammation: double trouble.Crossref | GoogleScholarGoogle Scholar | 32553197PubMed |
[26] Kessler RC, Birnbaum HG, Shahly V, et al. Age differences in the prevalence and co-morbidity of dsm-iv major depressive episodes: results from the WHO world mental health survey initiative. Depress Anxiety 2010; 27 351–64.
| Age differences in the prevalence and co-morbidity of dsm-iv major depressive episodes: results from the WHO world mental health survey initiative.Crossref | GoogleScholarGoogle Scholar | 20037917PubMed |
[27] Bushnell GA, Stürmer T, Gaynes BN, et al. Simultaneous antidepressant and benzodiazepine new use and subsequent long-term benzodiazepine use in adults with depression, United States, 2001-2014. JAMA Psychiatry 2017; 74 747–55.
| Simultaneous antidepressant and benzodiazepine new use and subsequent long-term benzodiazepine use in adults with depression, United States, 2001-2014.Crossref | GoogleScholarGoogle Scholar | 28593281PubMed |
[28] Chen LY, Crum RM, Martins SS, et al. Service use and barriers to mental health care among adults with major depression and comorbid substance dependence. Psychiatr Serv 2013; 64 863–70.
| Service use and barriers to mental health care among adults with major depression and comorbid substance dependence.Crossref | GoogleScholarGoogle Scholar | 23728427PubMed |
[29] Courtet P, Lopez-Castroman J, Jaussent I, et al. Antidepressant dosage and suicidal ideation. JAMA Intern Med 2014; 174 1863–5.
| Antidepressant dosage and suicidal ideation.Crossref | GoogleScholarGoogle Scholar | 25243608PubMed |
[30] Perroud N, Bondolfi G, Uher R, et al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics 2011; 12 365–77.
| Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample.Crossref | GoogleScholarGoogle Scholar | 21449676PubMed |
[31] Whitely M, Raven M, Jureidini J. Antidepressant prescribing and suicide/self-harm by young Australians: regulatory warnings, contradictory advice, and long-term trends. Front Psychiatry 2020; 11 478
| Antidepressant prescribing and suicide/self-harm by young Australians: regulatory warnings, contradictory advice, and long-term trends.Crossref | GoogleScholarGoogle Scholar | 32587531PubMed |
[32] Mangoni AA. Predicting and detecting adverse drug reactions in old age: Challenges and opportunities. Expert Opin Drug Metab Toxicol 2012; 8 527–30.
| Predicting and detecting adverse drug reactions in old age: Challenges and opportunities.Crossref | GoogleScholarGoogle Scholar | 22512705PubMed |
[33] Temple ME, Robinson RF, Miller JC, et al. Frequency and preventability of adverse drug reactions in paediatric patients. Drug Saf 2004; 27 819–29.
| Frequency and preventability of adverse drug reactions in paediatric patients.Crossref | GoogleScholarGoogle Scholar | 15350153PubMed |
[34] Dragioti E, Solmi M, Favaro A, et al. Association of antidepressant use with adverse health outcomes: a systematic umbrella review. JAMA Psychiatry 2019; 76 1241–55.
| Association of antidepressant use with adverse health outcomes: a systematic umbrella review.Crossref | GoogleScholarGoogle Scholar | 31577342PubMed |
[35] Kreijkamp-Kaspers S, McGuire T, Bedford S, et al. Your questions about complementary medicines answered. Aust Fam Physician 2015; 44 373–4.
| 26209986PubMed |
[36] Busato A, Dönges A, Herren S, et al. Health status and health care utilisation of patients in complementary and conventional primary care in Switzerland - an observational study. Fam Pract 2006; 23 116–24.
| Health status and health care utilisation of patients in complementary and conventional primary care in Switzerland - an observational study.Crossref | GoogleScholarGoogle Scholar | 16115833PubMed |
[37] Moses GM, McGuire TM. Drug interactions with complementary medicines. Aust Prescr 2010; 33 177–80.
| Drug interactions with complementary medicines.Crossref | GoogleScholarGoogle Scholar |
[38] van Geffen ECG, van Hulten R, Bouvy ML, et al. Characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor treatment. Ann Pharmacother 2008; 42 218–25.
| Characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor treatment.Crossref | GoogleScholarGoogle Scholar |
[39] Palleria C, Di Paolo A, Giofrè C, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci 2013; 18 601–10.
| 24516494PubMed |
[40] Hengen KM, Alpers GW. What’s the risk? Fearful individuals generally overestimate negative outcomes and they dread outcomes of specific events. Front Psychol 2019; 10 1676
| What’s the risk? Fearful individuals generally overestimate negative outcomes and they dread outcomes of specific events.Crossref | GoogleScholarGoogle Scholar | 31417450PubMed |
[41] Loewenstein GF, Weber EU, Hsee CK, et al. Risk as feelings. Psychol Bull 2001; 127 267–86.
| Risk as feelings.Crossref | GoogleScholarGoogle Scholar | 11316014PubMed |
[42] Australian Bureau of Statistics. Families in regional, rural and remote Australia 2006 census data. Canberra: Australian Government; 2010. Available at https://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/1379.0.55.001Explanatory%20Notes12002-2006?OpenDocument [Accessed 7 December 2021]
[43] Pohjanoksa-Mäntylä M. Medicines information sources and services for consumers: A special focus on the internet and people with depression (dissertation). Helsinki: University of Helsinki; 2010. p. 142.
[44] Coman GJ, Burrows GD, Evans BJ. Telephone counselling in Australia: applications and considerations for use. Br J Guid Counc 2001; 29 247–58.
| Telephone counselling in Australia: applications and considerations for use.Crossref | GoogleScholarGoogle Scholar |
[45] Burgess N, Christensen H, Leach LS, et al. Mental health profile of callers to a telephone counselling service. J Telemed Telecare 2008; 14 42–7.
| Mental health profile of callers to a telephone counselling service.Crossref | GoogleScholarGoogle Scholar | 18318929PubMed |
[46] Arroll B, Goodyear-Smith F, Kerse N, et al. The prevalence of depression among Maori patients in Auckland general practice. J Prim Health Care 2009; 1 26
| 20690483PubMed |
